Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation

Hematological Malignancy Clinical Trial

— DLI-NK  

Official title:

Phase I of Infusion of Selected Donor NK Cells After HLA Identical Allogeneic Stem Cell Transplantation Prepared With Reduced Intensity Conditioning - DLI-NK/IPC 2012-003

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01853358
• Other study ID #: DLI-NK/IPC 2012-003
• Status: Completed
• Phase: Phase 1
• Start date: April 2013
• Est. completion date: March 15, 2018

Study information

• Verified date: July 2018
• Source: Institut Paoli-Calmettes
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of our study will be to determine the clinical and biological safety of infusing immuno-selected NK (Natural Killer) CD3-/CD56+ cells, early after allogeneic transplantation with colony stimulating factor (G-CSF) mobilized peripheral blood stem cells and Reduced Intensity Conditioning (RIC), as a potential substitute to usual "Donor Lymphocyte Infusion" (DLI), that contain the whole range of immune effectors. The trial will include several progressive steps: dose escalation up to a level compatible with the cost-effectiveness potential of the device and clinical situation and recombinant interleukin-2 (r-IL2) activation of selected NK cells in vitro prior to re-infusion.

Description:

In the mid 90's, it has been shown that donor lymphocyte infusions (DLI), when given for Chronic Myelocytic Leukemia (CML) that has relapsed after conventional allogeneic stem cell transplantation (SCT), result in a high incidence of durable cytogenetic and molecular remissions. However, regular documented effects are the occurrence of secondary aplasia and/or graft-versus-host disease (GVHD) including the post RIC situation. These effects are related to the high content of cytotoxic T cells in the DLI. Attempts to deplete CD8+ T-cells from DLI have been conducted with promising results but are not totally satisfactory.

More recently the infusion of r-IL2 ex-vivo activated autologous or allogeneic NK-selected cells have been studied and the safety established in patients presenting various malignancies.

Indeed, NK are thoroughly characterized in terms of genotype, phenotype and function. Although a handful of clinical-grade reagents and devices exist that give access to the human NK cell compartment, an immuno-selection device exists that allows for the selection of NK cells from various types of hematopoietic cell collections in view of clinical applications: the process produces CD3-/CD56+ cells in two steps and have been used in the previous experiences.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: March 15, 2018
• Est. primary completion date: March 15, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Patient treated with allogeneic stem cell transplantation

• Presenting an hematological malignancy with an intermediate, high or very high risk index according to the disease risk index developed by the Dana Farber Cancer Institute

• Donor: HLA matched related or unrelated (10/10) donor

• Graft: Peripheral stem cell transplant

• Reduced Intensity Conditioning as used in the current transplant program:

Fludarabine, IV Busulfan and Thymoglobuline

2. Age above 18 and under 70

3. Eastern Cooperative Oncology Group (ECOG) 0-1 or Karnofsky index = 70 %

4. Survival expectation > 6 months

5. Affiliation to social security

6. Signed informed consent from Donor and Patient

Exclusion Criteria:

1. Active grade >= 2 acute GVHD or corticotherapy = 0.5 mg/kg/day at time of NK cell infusion

2. Active infection

3. Psychiatric disorder occurring after transplant

4. Pregnant or breast-feeding women or without contraception

Related Conditions & MeSH terms

• Hematological Malignancy
• Neoplasms

Intervention

Biological:
• NK Cell infusion
level 1: 1 x 10e6 NK cells /kg; level 2: 5 x 10e6 NK cells /kg; level 3: > 5.10e6 and = 5.10e7 cellules NK/kg

Locations

Country	Name	City	State
France	Institut Paoli-Calmettes	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Institut Paoli-Calmettes

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurence of grade 3-4 toxicity within 30 days of NK cells infusion	To establish the safety of donor NK cells infusion after HLA matched allogeneic transplant prepared by RIC.	day 30
Secondary	Number of infused cells population : CD3+, CD56+/CD16+, CD56-/CD16+, CD56+/CD16- (Determination)	Ex vivo NK cell selection reproductibility	baseline: at the time of the NK cells infusion
Secondary	relapse		up to one year after infusion
Secondary	number of NK cells function form baseline to Month 12 (kinetics)	Immunomonitoring: NK ontogeny after in vivo transfer, characterization of KIR expression (phenotype and genotype), documentation of functional activity against tumor cell line and EBV transformed B cell lines. These studies will allow calibrating further the kinetics of NK cells function (cytotoxicity and cytokine production) as well to answer different questions of fundamental immunology; The following studies will be performed: Analysis of early steps of aGVHD, immune activation and toxicity; Impact of the infusions on NK reconstitution and myeloid cells including dendritic cells; Antileukemic effects	at Day1, Day2, Day9, Day30, Month3, Month6, Month12

External Links

•   official web site of the sponsor